This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Desai, J. Articles by Demetri, G. D. Search for Related Content PubMed PubMed Citation Articles by Desai, J. Articles by Demetri, G. D. Related Collections Commentary

Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors

Authors' Affiliations: ¹ Dana-Farber Cancer Institute and Harvard Medical School; ² Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; and ³ Oregon Health and Science University Cancer Institute & Portland VA Medical Center, Portland, Oregon

Requests for reprints: George Demetri, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, SW530, 44 Binney Street, Boston, MA 02115. Phone: 617-632-632-5942; Fax: 617-632-3408; E-mail: george_demetri{at}dfci.harvard.edu.

Purpose: Resistance to imatinib mesylate is emerging as a clinical challenge in patients with metastatic gastrointestinal stromal tumors (GIST). Novel patterns of progression have been noted in a number of these patients. The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression.

Experimental Design: Patients with metastatic GIST treated with imatinib were followed with serial computed tomography/magnetic resonance imaging and [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography. Where feasible, biopsies were done to document disease progression.

Results: A total of 89 patients were followed for a median of 43 months. Forty-eight patients developed progressive disease. A unique "resistant clonal nodule" pattern (defined as a new enhancing nodular focus enclosed within a preexisting tumor mass) was seen in 23 of 48 patients and was thought to represent emergence of clones resistant to imatinib. Nodules were demonstrable a median of 5 months (range, 0-13 months) before objective progression defined by tumor size criteria and were the first sign of progression in 18 of 23 patients. Median survival among patients whose first progression was nodular was 35.1 months, compared with 44.6 months for patients whose first progression met Southwest Oncology Group criteria (P = 0.31). Comparative tumor biopsies were done in 10 patients at baseline and from progressing nodules. Genotypic analyses of KIT and PDGFRA kinases were done, revealing new activating kinase mutations in 80% (8 of 10) of these patients.

Conclusion: The resistant clonal nodule is a unique pattern of disease progression seen in patients with GISTs after an initial response to imatinib and reflects the emergence of imatinib-resistant clones. Conventional tumor measurements (Southwest Oncology Group/Response Evaluation Criteria in Solid Tumors) do not detect this subtle finding. A new enhancing nodule growing within a preexisting tumor mass should be classified as a new lesion and be regarded, at least, as partial progression of GIST.

Commentary

Progressive Thoughts about Progressive Disease

Neil P. Shah
Clin. Cancer Res. 2007 13: 5229-5231. [Full Text] [PDF]

This article has been cited by other articles:

				N. P. Shah Progressive Thoughts about Progressive Disease Clin. Cancer Res., September 15, 2007; 13(18): 5229 - 5231. [Full Text] [PDF]